Loading clinical trials...
Loading clinical trials...
Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma
Conditions
Interventions
rosiglitazone maleate
Locations
1
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
October 1, 1999
Primary Completion Date
March 1, 2006
Completion Date
May 1, 2015
Last Updated
June 26, 2023
NCT04704661
NCT05039801
NCT06066138
NCT03715933
NCT07479732
NCT07156565
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions